2017 ACVIM Forum Research Abstract Program

Histology confirmed hepatic disease in all dogs (Idiopathic chronic hepatitis; n = 12; Copper-associated hepatopathy: n = 5; Hydropic/Vacuolar: n = 5; Non-specific reactive: n = 3; Vascular: n = 1; Lymphoma: n = 1). 18/27 (67%) dogs had at least one coagulation abnormality. 5/27 (19%) dogs had Gelfoam Ã’ placed to aid hemostasis in one or more biopsy sites. Hypoalbuminemia (P = 0.009), decreased antithrombin activity (P = 0.003), and older age (P = 0.038) were associated with the use of Gelfoam Ã’ . 14/27 (52%) dogs had abnormal platelet aggregometry, including all 5 dogs who received Gelfoam Ã’ . Abnormal platelet aggregometry was associated with the use of Gelfoam Ã’ to aid in hemostasis (P = 0.041). Prolonged PT or APTT were not associated with use of Gelfoam Ã’ . Hypofibrinogenemia was also not associated with Gelfoam Ã’ use, but was correlated with hypoalbuminemia (P = 0.042). Bleeding was controlled with Gelfoam Ã’ intervention alone in all dogs. One dog sustained a splenic laceration during entry into the abdomen, but hemostasis was achieved quickly. Otherwise, no significant complications occurred.